Search results
Moderna Has Big AI News. Is the Stock a Buy?
Motley Fool via Yahoo Finance· 1 day agoLet's find out. Image source: Getty Images. Moderna's peak vaccine revenue First, a quick summary of where Moderna stands right now.
Could Novavax Become the Next Moderna?
Motley Fool via Yahoo Finance· 6 days agoThe Sanofi agreement even prompted Novavax to say it now no longer is at risk of shutting its doors. But does this mean Novavax could become a leader in...
3 Things You Need to Know If You Buy Novavax Today | The Motley Fool
The Motley Fool· 1 day agoNovavax (NVAX 5.30%) stock has both soared and plummeted at times in recent years. Investors...
Free COVID-19 vaccines could be a thing of the past as federal program is set to expire early
Chicago Sun-Times· 16 hours agoWhen COVID-19 vaccines entered the commercial market, the federal government introduced a program to...
Better Buy: Inovio Pharmaceuticals vs. Novavax
Motley Fool via Yahoo Finance· 1 day agoThe COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller biotechs that tried to...
mRNA Vaccines vs. the Pandemic
The North Coast Journal· 12 hours agoAbout 13 billion doses of mRNA vaccines against the virus have now been given in 184 countries, including 600 million in the U.S. alone. While some 7...
This Stock Just More Than Doubled in 1 Day: Is It a Buy?
Motley Fool via Yahoo Finance· 4 days agoBut what if it succeeds? Moderna, Pfizer, and now Sanofi are developing competing combination ...
Orna, a circular RNA specialist, acquires a buzzy startup
BioPharma Dive via Yahoo Finance· 7 hours agoAfter laying off staff late last year, Orna is expanding through the purchase of ReNAgade...
Evolving With the Virus: Repeat COVID-19 Shots Neutralizing Beyond the Expected
SciTechDaily· 19 hours agoThe response to an updated vaccine is influenced by previous vaccinations but also produces broadly...
Iran's new president's link to COVID vaccine
Newsweek· 3 days agoNew interim Iranian President Mohammad Mokhber received scrutiny for his role in the lack of development of a domestic vaccine at the height of the...
